<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>27386685</identifier>
<setSpec>0034-0634</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Somacarrera Pérez, Ma Luisa</dc:author>
<dc:author>López Sánchez, Antonio</dc:author>
<dc:author>Lucas González, Mónica</dc:author>
<dc:author>Lucas González, Ignacio</dc:author>
<dc:author>Lucas Tomás, Miguel</dc:author>
<dc:author>Hernández Vallejo, Gonzálo</dc:author>
<dc:description xml:lang="en">The Diffuse Large B-Cell Lymphoma is the most frequent non Hodgkin Lymphoma. The role of CT/PET in this relatively homogeneous group of lymphomas is controversial. It rarely changes the management of the patients in the initial staging. Recents publications, clinical trials and experts consensus meetings have demonstrated its utility in the evaluation of the response at the end of the treatment. The interest of CT/PET in the evaluation of the response during the treatment, with the objective of implement a "Risk Adapted Therapy", in increasing.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2014 </dc:date>
<dc:title xml:lang="es">CÁNCER OROFARINGEO: LA CÉLULA ESPINOSA.</dc:title>
<dc:title xml:lang="en">[OROPHARYS CANCER: THE SQUAMOUS CELL].</dc:title>
<dc:publisher>Anales de la Real Academia Nacional de Medicina</dc:publisher>
</metadata>
</record>
</pubmed-document>
